Autoimmune Pancreatitis

Terumi Kamisawa, MD, Tokyo Metropolitan Komagome Hospital, Department of Internal Medicine, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan Jae Bock Chung MD Ph.D., Yonsei University College of Medicine, Department of Internal Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 120-752 Seoul, Korea, Republic of (South Korea)

This book provides up-to-date information on all aspects of autoimmune pancreatitis, a unique form of pancreatitis characterized clinically by frequent presentation with obstructive jaundice and dramatic response to steroids, histologically by a lymphoplasmacytic infiltrate with fibrosis, and radiologically by pancreatic enlargement. Current concepts regarding the disease and its classification into subtypes 1 and 2 are explained, and clinical, serological, and histopathological findings are carefully described. Imaging features on all the relevant modalities are illustrated, covering both the pancreas and other involved organs. Current and emerging therapeutic strategies, including steroids, immunomodulatory drugs, and rituximab, are then discussed. The reader will find the book to be an excellent aid to the diagnosis of autoimmune pancreatitis and its differentiation from pancreatobiliary malignancies, as well as a clear guide to treatment.

Clarifies current concepts regarding autoimmune pancreatitis and its subtypes

Preface.- Part 1. Overview of type 1 and type 2.- Part 2. Epidemiology.- Part 3. Pathophysiology.- Part 4. Pathology.- Part 5. Clinical features.- Part 6. Pancreatic endocrine and exocrine functions.- Part 7. Serology.- Part 8. Diagnostic criteria.- Part 9. Imaging.- Abdominal ultrasonography.- CT and MRI with MRCP.- Endoscopy; ERCP and EUS.- PET-CTNobumasa Mizuno.- Part 10. Tissue acquisition for histologic diagnosis.- Part 11. Other organ involvements.- Sclerosing cholangitis.- Sialadenitis and dacryoadenitis.- Retroperitoneal fibrosis.- Renal lesions.- Pulmonary lesions.- Lymphadenopathy.- GI tract.- Part 12. Treatment.- Steroids.- Immunomodulatory drugs and rituximab.- Relapse.- Part 13. Prognosis.- Development to chronic pancreatitis.- Occurrence of malignant neoplasms.- Part 14. Type 2 AIP.- Part 15. International survey.- Part 16. AIP in the USA.- Part 17. AIP in Europe.- Part 18. Future perspective.